Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy
ABSTRACT Despite evidence of a chronic inflammatory phenotype in people living with HIV (PLWH) on antiretroviral therapy (ART), the role of oral microbiota in chronic immune activation has not been fully explored. We aimed to determine the relationship between oral and gut microbiome diversity and c...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
American Society for Microbiology
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0cb9fe476054456491e7cf070fe89589 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:0cb9fe476054456491e7cf070fe89589 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:0cb9fe476054456491e7cf070fe895892021-11-15T15:27:53ZOral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy10.1128/mSphere.00798-192379-5042https://doaj.org/article/0cb9fe476054456491e7cf070fe895892020-02-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mSphere.00798-19https://doaj.org/toc/2379-5042ABSTRACT Despite evidence of a chronic inflammatory phenotype in people living with HIV (PLWH) on antiretroviral therapy (ART), the role of oral microbiota in chronic immune activation has not been fully explored. We aimed to determine the relationship between oral and gut microbiome diversity and chronic systemic inflammation in ART-treated PLWH with prevalent severe periodontitis, an inflammatory condition commonly associated with HIV infection. We assessed bacterial and fungal communities at oral and gastrointestinal sites in a cohort (n = 52) of primarily postmenopausal women on ART using 16S rRNA and internal transcribed spacer (ITS) sequencing and measured cellular and soluble markers of inflammation and immune dysfunction. Linear mixed-effect regression and differential abundance analyses were used to associate clinical characteristics and immunological markers with bacterial and fungal diversity and community composition. Bacterial α-diversity in plaque, saliva, and gut was associated with different immunological markers, while mycobial diversity was not associated with soluble or cellular biomarkers of immune stimulation or T cell dysfunction. Furthermore, lipopolysaccharide-positive (LPS+) bacteria previously linked to inflammatory outcomes were enriched at oral sites in patients with severe periodontitis. Fungal α-diversity was reduced in plaque from teeth with higher clinical attachment loss, a marker of periodontitis, and in saliva and plaque from patients with a history of AIDS. Our results show that both bacterial and fungal oral microbiome communities likely play a role in chronic systemic immune activation in PLWH. Thus, interventions targeting both inflammation and the microbiome, particularly in the oral cavity, may be necessary to reduce chronic immune dysregulation in patients with HIV. IMPORTANCE A feedback loop between dysbiotic gut microbiota, increased translocation of microbial products such as lipopolysaccharide, and inflammation has been hypothesized to cause immune system dysfunction in early HIV infection. However, despite evidence of a chronic inflammatory phenotype in patients on antiretroviral therapy (ART), the role of oral microbiota in systemic immune activation and the relationship between oral and gut bacterial and fungal diversity have not been explored. Our study suggests a crucial role for oral bacterial and fungal communities in long-term systemic immune activation in patients on ART, expanding the current paradigm focused on gut bacteria. Our results indicate that interventions targeting both inflammation and microbial diversity are needed to mitigate oral inflammation-related comorbidities, particularly in HIV-positive patients. More broadly, these findings can bolster general models of microbiome-mediated chronic systemic immune activation and aid the development of precise microbiota-targeted interventions to reverse chronic inflammation.Medini K. AnnavajhalaSabrina D. KhanSean B. SullivanJayesh ShahLauren PassKarolina KisterHeather KunenVictor ChiangGwennaëlle C. MonnotChristopher L. RicuperoRebecca A. MazurPeter GordonAnnemieke de JongSunil WadhwaMichael T. YinRyan T. DemmerAnne-Catrin UhlemannAmerican Society for Microbiologyarticleoral microbiomeantiretroviral therapymycobiomeimmune system activationHIVantiretroviral agentsMicrobiologyQR1-502ENmSphere, Vol 5, Iss 1 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
oral microbiome antiretroviral therapy mycobiome immune system activation HIV antiretroviral agents Microbiology QR1-502 |
| spellingShingle |
oral microbiome antiretroviral therapy mycobiome immune system activation HIV antiretroviral agents Microbiology QR1-502 Medini K. Annavajhala Sabrina D. Khan Sean B. Sullivan Jayesh Shah Lauren Pass Karolina Kister Heather Kunen Victor Chiang Gwennaëlle C. Monnot Christopher L. Ricupero Rebecca A. Mazur Peter Gordon Annemieke de Jong Sunil Wadhwa Michael T. Yin Ryan T. Demmer Anne-Catrin Uhlemann Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy |
| description |
ABSTRACT Despite evidence of a chronic inflammatory phenotype in people living with HIV (PLWH) on antiretroviral therapy (ART), the role of oral microbiota in chronic immune activation has not been fully explored. We aimed to determine the relationship between oral and gut microbiome diversity and chronic systemic inflammation in ART-treated PLWH with prevalent severe periodontitis, an inflammatory condition commonly associated with HIV infection. We assessed bacterial and fungal communities at oral and gastrointestinal sites in a cohort (n = 52) of primarily postmenopausal women on ART using 16S rRNA and internal transcribed spacer (ITS) sequencing and measured cellular and soluble markers of inflammation and immune dysfunction. Linear mixed-effect regression and differential abundance analyses were used to associate clinical characteristics and immunological markers with bacterial and fungal diversity and community composition. Bacterial α-diversity in plaque, saliva, and gut was associated with different immunological markers, while mycobial diversity was not associated with soluble or cellular biomarkers of immune stimulation or T cell dysfunction. Furthermore, lipopolysaccharide-positive (LPS+) bacteria previously linked to inflammatory outcomes were enriched at oral sites in patients with severe periodontitis. Fungal α-diversity was reduced in plaque from teeth with higher clinical attachment loss, a marker of periodontitis, and in saliva and plaque from patients with a history of AIDS. Our results show that both bacterial and fungal oral microbiome communities likely play a role in chronic systemic immune activation in PLWH. Thus, interventions targeting both inflammation and the microbiome, particularly in the oral cavity, may be necessary to reduce chronic immune dysregulation in patients with HIV. IMPORTANCE A feedback loop between dysbiotic gut microbiota, increased translocation of microbial products such as lipopolysaccharide, and inflammation has been hypothesized to cause immune system dysfunction in early HIV infection. However, despite evidence of a chronic inflammatory phenotype in patients on antiretroviral therapy (ART), the role of oral microbiota in systemic immune activation and the relationship between oral and gut bacterial and fungal diversity have not been explored. Our study suggests a crucial role for oral bacterial and fungal communities in long-term systemic immune activation in patients on ART, expanding the current paradigm focused on gut bacteria. Our results indicate that interventions targeting both inflammation and microbial diversity are needed to mitigate oral inflammation-related comorbidities, particularly in HIV-positive patients. More broadly, these findings can bolster general models of microbiome-mediated chronic systemic immune activation and aid the development of precise microbiota-targeted interventions to reverse chronic inflammation. |
| format |
article |
| author |
Medini K. Annavajhala Sabrina D. Khan Sean B. Sullivan Jayesh Shah Lauren Pass Karolina Kister Heather Kunen Victor Chiang Gwennaëlle C. Monnot Christopher L. Ricupero Rebecca A. Mazur Peter Gordon Annemieke de Jong Sunil Wadhwa Michael T. Yin Ryan T. Demmer Anne-Catrin Uhlemann |
| author_facet |
Medini K. Annavajhala Sabrina D. Khan Sean B. Sullivan Jayesh Shah Lauren Pass Karolina Kister Heather Kunen Victor Chiang Gwennaëlle C. Monnot Christopher L. Ricupero Rebecca A. Mazur Peter Gordon Annemieke de Jong Sunil Wadhwa Michael T. Yin Ryan T. Demmer Anne-Catrin Uhlemann |
| author_sort |
Medini K. Annavajhala |
| title |
Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy |
| title_short |
Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy |
| title_full |
Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy |
| title_fullStr |
Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy |
| title_full_unstemmed |
Oral and Gut Microbial Diversity and Immune Regulation in Patients with HIV on Antiretroviral Therapy |
| title_sort |
oral and gut microbial diversity and immune regulation in patients with hiv on antiretroviral therapy |
| publisher |
American Society for Microbiology |
| publishDate |
2020 |
| url |
https://doaj.org/article/0cb9fe476054456491e7cf070fe89589 |
| work_keys_str_mv |
AT medinikannavajhala oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT sabrinadkhan oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT seanbsullivan oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT jayeshshah oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT laurenpass oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT karolinakister oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT heatherkunen oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT victorchiang oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT gwennaellecmonnot oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT christopherlricupero oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT rebeccaamazur oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT petergordon oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT annemiekedejong oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT sunilwadhwa oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT michaeltyin oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT ryantdemmer oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy AT annecatrinuhlemann oralandgutmicrobialdiversityandimmuneregulationinpatientswithhivonantiretroviraltherapy |
| _version_ |
1718427930398294016 |